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Abstract
The yeast Saccharomyces boulardii is well known for its probiotic effects such as treating or preventing gastrointestinal diseases.
Due to its ability to survive in stomach and intestine, S. boulardii could be applied as a vehicle for producing and delivering
bioactive substances of interest to human gut. In this study, we cloned the gene lecC encoding the antilisterial peptide leucocin C
from lactic acid bacterium Leuconostoc carnosum in S. boulardii. The constructed S. boulardii strain secreted a peptide, which
had molecular weight corresponding to leucocin C in SDS-PAGE. The peptide band inhibited Listeria monocytogenes in gel
overlay assay. Likewise, concentrated S. boulardii culture supernatant inhibited the growth of L. monocytogenes. The growth
profile and acid tolerance of the leucocin C secreting S. boulardiiwere similar as those of the strain carrying the empty vector. We
further demonstrated that the cells of the leucocin C producing S. boulardii efficiently killed L. monocytogenes, also without
antibiotic selection pressure. These results showed that antilisterial activity could be added to the arsenal of probiotic activities of
S. boulardii, demonstrating its potential as a carrier for therapeutics delivery.
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Introduction
The probiotic yeast Saccharomyces boulardii, originally iso-
lated from litchi fruit by Henri Boulard in the 1920s, is a
subtype of Saccharomyces cerevisiae [1]. S. boulardii is the
only approved probiotic yeast in human nutrition [2] and has
been granted with the GRAS (generally regarded as safe) sta-
tus by the Food and Drug Administration (FDA) of USA [3].
The benefits of S. boulardii have been widely assessed.
Controlled clinical trials have indicated that oral administra-
tion of S. boulardii can treat or prevent gastrointestinal dis-
eases such as antibiotic-associated diarrhea [4], acute diarrhea
in children [5, 6], and AIDS-associated diarrhea [7].
Additionally, some studies have revealed that S. boulardii
can control inflammation in the inflammatory bowel disease
(IBD) like Crohn’s disease and ulcerative colitis [8].
Despite the probiotic effects of S. boulardii are well under-
stood, only a few studies have focused on expanding its pro-
biotic properties by production of heterologous proteins, such
as cytokines or antimicrobial proteins. In the previous work,
Douradinha et al. [9] investigated factors concerning the ge-
netic manipulation of S. boulardii, such as plasmids transfor-
mation and screening of positive strains. Regarding heterolo-
gous protein expression, researchers have produced mouse
interleukin-10 (IL-10) [10, 11] and Microneme-2 proteins of
chicken parasite Eimeria tenella [12] in S. boulardii using
antibiotics as selection markers. In addition, green fluorescent
protein (GFP) [13], human lysozyme [14], and ovalbumin
(OVA) [15] have been secreted in auxotrophic mutant of
S. boulardii. Thus, regardless of the limited number of genetic
studies, it is possible to produce heterologous proteins in
S. boulardii. As a carrier to deliver drugs or antimicrobial
agents to gastrointestinal tracts for treating disorders or killing
pathogens, S. boulardii is more suitable than S. cerevisiae, due
to the better tolerance of S. boulardii to high temperature and
low pH [1]. To the best of our knowledge, so far there are no
studies reported about the production of antimicrobial proteins
from bacteria in S. boulardii.
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Bacteriocins are ribosomally synthesized antimicrobial
proteins produced by bacteria. Studies have shown that a large
amount of lactic acid bacteria (LAB) strains including
Lactobacillus, Lactococcus, and Leuconostoc can secrete bac-
teriocins, of which many have been well characterized [16].
Bacteriocins generally comprise three classes [17]. Among the
class II group, the subgroup class IIa (pediocin-like) bacterio-
cins have high killing activity against Listeria monocytogenes
[18] by holing its cell membrane and causing internals release
[19]. L. monocytogenes is a foodborne pathogen and widely
distributed in the environment, including water [20], foods
[21], and human feces [22]. In human, L. monocytogenes
causes infection known as listeriosis, one of the most severe
foodborne diseases [23]. In 2017, there were 786 listeriosis
cases reported in the USA [24] and 2480 cases in EU [25].
In our previous work, we have successfully produced the
class IIa bacteriocin leucocin C from Leuconostoc carnosum
4010 [26] in Lactococcus lactis NZ9000 [27]. Therefore, in
this present study, we chose leucocin C as the target antimi-
crobial peptide. The main aim was to design a recombinant
S. boulardii strain, which could produce antilisterial leucocin
C besides its probiotic characteristics. Based on the results of
antimicrobial tests, SDS-PAGE, gel overlay assay, and
L. monocytogenes killing assay, active leucocin C was shown
to be successfully secreted by S. boulardii. The benefits of
S. boulardii could thus be enhanced with the combination of
antimicrobial and probiotic effects.
Materials and Methods
Plasmids, Strains, and Media
All the plasmids and strains used in this study are listed in
Table 1. Escherichia coli DH5α was grown in LB medium
(1% tryptone, 0.5% yeast extract, 1% NaCl) at 37 °C, supple-
mented with kanamycin (50 μg/ml) for selecting the
transformants. Saccharomyces boulardii CNCM I-745 was
grown in YPD medium (1% yeast extract, 2% peptone, 2%
glucose) at 37 °C, and 20 μg/ml blasticidin S (Thermo Fisher
Scientific, Waltham, MA, USA) was used to maintain plas-
mids in yeasts [28]. L. monocytogenes was grown in BHI
(brain heart infusion, Lab M, Lancashire, UK) agar or in broth
at 37 °C.
Plasmid and Transformants Construction
For heterologous expression of leucocin C in S. boulardii, the
plasmid pSF-TEF1-TPI1-Blast (pSF-Blast) was used as the
expression vector (Fig. 1). This vector carries a blasticidin S
resistance cassette (Blast), which is driven from the strong
yeast constitutive triosephosphate isomerase (TPI1) gene pro-
moter. Blast is the yeast selection marker, while the
kanamycin-resistant gene (KanR) is to select bacterial
transformants. The plasmid also contains a constitutive pro-
moter of yeast translation elongation factor 1 (TEF1), which is
the strongest promoter known for the protein expression in
S. cerevisiae [29, 30]. EcoRI and XbaI were selected as the
restriction sites for the gene insertion.
The DNA fragment for the leucocin C secretion (Fig. 1)
was synthesized by GenScript (Piscataway, NJ, USA). This
fragment consists of the S. cerevisiae α-mating factor signal
sequence to guide the extracellular secretion [31] and the lecC
gene sequence [27]. Codon optimization was achieved by
GenScript using OptimumGene™ algorithm to enhance the
efficiency of gene expression. After optimization, the synthe-
sized fragment was cloned into pSF-Blast plasmid at the
EcoRI/XbaI sites. To increase the amount of plasmid for yeast
transformation, the resulting plasmid pSF-Blast-lecC (pSF-
TEF1-TPI1-Blast-lecC) was introduced into E. coli DH5α
by electroporation [32]. Afterwards, the enriched pSF-Blast-
lecC plasmid was isolated from E. coli with EZ-10 Spin
Column Plasmid Mini-Preps Kit (BBI Life Sciences,
Shanghai, China).
After that, 2.7 μg of recombinant plasmid was transferred
into S. boulardii via electroporation [33]. Correct
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transformants were identified by PCR using the plasmid spe-
cific primers (F, 5′-CATATCACATAGGAAGCAACAG-3′,
hybridizing before the TEF1 promoter; R, 5′-CTAC
GATACCGATAGAGATGG-3′, hybridizing before T7 ter-
minator), which resulted in PCR products of 1400 bp from
pSF-Blast-lecC and 1050 bp from the plain vector.
Secretion of Leucocin C
For the production of leucocin C, S. boulardii carrying pSF-
Blast-lecC (Sb-LecC) was grown in 250 ml of broth at 37 °C
for 36 h with shaking. S. boulardii wild type (Sb-wild type)
and S. boulardii carrying empty vector pSF-TEF1-TPI1-Blast
(Sb-vector) were used as negative controls. Cell-free superna-
tants were collected by centrifugation at 5000×g for 10 min at
4 °C and filtered through the 0.22-μm sterilized Millipore
filter (Merck Millipore, Bedford, MA, USA). The leucocin
C in the cell-free supernatant of Sb-LecC was precipitated
with 40% ammonium sulfate and collected by centrifugation
at 10,000×g for 30 min as previously described [26, 34]. The
protein precipitation was dissolved in 500 μl of 20 mM PBS
buffer (pH 7.2). The final concentrated samples were kept at −
20 °C for further tests. The concentrated supernatant from the
leucocin C producing L. lactis NZ9000 constructed in our
previous study [27] was used as a positive control.
Antimicrobial Tests
An agar inhibition assay [35] was performed to roughly esti-
mate the antimicrobial activity of recombinant S. boulardii
cells. Yeast cells were grown in the YPD liquid culture over-
night and washed with Ringer’s solution (Sigma-Aldrich, St.
Louis, MO, USA) for two times. Ten microliters of the
washed cells were added and let dry on the Listeria indicator
plate. After overnight incubation, the inhibition halos were
observed to determine the antimicrobial activity of yeast cells.
The bacteriocin activity of the concentrated supernatant
was then tested by using agar well diffusion assay [36]. The
indicator strain L. monocytogenes was grown for overnight
and spread onto the BHI agar plate. Wells were made on the
plate with sterile cork borer (7 mm in diameter, MRS
Scientific Ltd., Wickford, UK), and the bottom of well was
sealed with 20 μl of agar. After the concentrated supernatant
was loaded, plates were incubated overnight at 37 °C.
Identification of Leucocin C Using SDS-PAGE and Gel
Overlay
Tricine-SDS-PAGE (16.5% resolving gel, 10% spacer gel)
[37] and gel overlay assay [38] were performed to verify the
presence of leucocin C in the supernatant. For SDS-PAGE,
proteins from 100 μl of concentrated supernatant were
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Fig. 1 Construction of the plasmid pSF-Blast-lecC. The lecC expression
cassette was cloned into EcoRI and XbaI sites in the vector pSF-TEF1-
TPI1-Blast (OG539), resulting in the leucocin C secretion plasmid pSF-
TEF1-TPI1-Blast-lecC. The red arrows on the plasmid map indicate the
location where the plasmid specific primers would bind
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collected with 10 μl of StrataClean resin (Agilent
Technologies, Santa Clara, CA, USA). The resin beads were
resuspended with 40 μl of Tricine-SDS-PAGE loading buffer
(Bio-Rad, Hercules, CA, USA) to release the proteins. The
mixture was boiled for 3 min and insoluble fraction was re-
moved by centrifugation (10,000×g, 1 min). The soluble pro-
teins were then analyzed by Tricine-SDS-PAGE. Two identi-
cal gels were prepared under the same condition. Ten micro-
liters of concentrated Sb-LecC supernatant was loaded into the
gel, and the electrophoresis was performed at 4 °C under 30 V
for 30 min and 200 V for the rest of 2 h. After electrophoresis,
SDS-PAGE gels were fixed for 30 min in the fixing solution
(50% methanol, 10% acetic acid, 100 mM ammonium ace-
tate). Then, one gel was stained with Coomassie Brilliant Blue
R-250 (Sigma-Aldrich). The other gel was rinsed in distilled
water for 2 h, then placed on BHI agar plate, and covered with
15 ml BHI soft agar containing 200 μl of the overnight culture
of L. monocytogenes. The plate with gel was incubated over-
night at 37 °C.
Growth Profile
Bioscreen C™ Automated Microbiology Growth Curve
Analysis System (Growth Curves, Helsinki, Finland) was
used to determine the growth profile of yeasts. A single colony
was inoculated into YPD medium and grown for overnight.
On the next day, the fresh overnight culture was transferred to
pre-warmed YPD medium with 2% inoculum. Two hundred
microliters of the mixture were loaded into the honeycomb
plate. The Bioscreen C™ system collected the optical density
at 600 nm (OD600) every 1 h at 37 °C with continuous shak-
ing. To measure the growth profile of yeasts under various pH
conditions, YPD media were adjusted to pH 2 or 4,
respectively.
L. monocytogenes Killing Assay Using Recombinant S.
boulardii Cells
In order to further quantify the capacity of Sb-LecC cells
against L. monocytogenes, we tested the antimicrobial activity
of the cell cultures without antibiotic selection pressure. First,
Sb-LecC and L. monocytogenes were separately grown over-
night. Colony forming unit (CFU) was calculated to obtain the
init ial cell numbers of L. monocytogenes . Then,
L. monocytogenes was serially diluted (up to 1:1000) with
Ringer’s solution. Sb-LecC cells were centrifuged and washed
two times with Ringer’s solution to remove the antibiotic
blasticidin S. After final resuspension in YPD medium,
900 μl of Sb-LecC cells were mixed with 100 μl of different
concentrations of L. monocytogenes. We used two experimen-
tal approaches: (i) yeasts and Listeria cells were incubated in
YPD medium with shaking, and (ii) mixed cells were centri-
fuged (5000×g, 3 min) to form a pellet, thereby reducing the
physical distance between the cells. After incubation at 37 °C
for 4 h, the viable cells of L. monocytogenes were determined
by colony counting after serial dilutions. Nystatin of 50 μg/ml
(Sigma-Aldrich) [39] was added into BHI plates to kill yeast
cells for counting Listeria colonies. Listeria incubated without
yeast and Listeria incubated with the yeast Sb-vector were
used as controls. Then, the survival ratio was calculated based
on the ratio between viable cell numbers and initial cell num-
bers of Listeria. If the survival ratio was less than one, we
would consider that Sb-LecC killed Listeria. Survival ratio
higher than one indicates that Listeria had grown.
Results
Cloning of the Leucocin C Gene lecC in S. boulardii
The aim of this work was to improve the probiotic potential of
S. boulardii CNCM I-745 by enabling it to secrete the antimi-
crobial peptide leucocin C from Leuconostoc carnosum. Our
strategy for this was to clone the leucocin C gene lecC with a
yeast secretion signal in a plasmid vector. The lecC expression
plasmid and the empty vector were then introduced into
S. boulardii, resulting in the strains Sb-LecC and Sb-vector.
The presence of the plasmids in S. boulardiiwas confirmed by
PCR using plasmid specific primers. Correct bands of 1400
and 1050 bp were obtained from Sb-LecC and Sb-vector,
respectively (Online Source 1). No band was obtained from
the S. boulardii wild-type strain.
Antimicrobial Activity of S. boulardii Sb-LecC
Antimicrobial activity of the constructed strain S. boulardii
Sb-LecC was tested against L. monocytogenes. In the agar
inhibition assay, Sb-LecC cells caused a clear inhibition zone
on Listeria lawn, whereas the Sb-wild type and Sb-vector did
not inhibit Listeria (Online Source 2a). To examine the secre-
tion of the antimicrobial substance, the strains were cultured in
liquid media. Concentrated supernatant of Sb-LecC and
leucocin C from L. lactis NZ9000 as a control showed inhibi-
tion against L. monocytogenes, whereas the supernatants from
Sb-wild type and Sb-vector were not antimicrobial (Online
Source 2b). These results demonstrated the secretion of
antilisterial compound by the Sb-LecC strain.
Identifying Leucocin C in Sb-LecC Growth Supernatant
To verify that the inhibition effect of the strain Sb-LecC was
caused by secreted leucocin C, concentrated cell-free supernatant
of the Sb-LecC was analyzed in Coomassie-stained SDS-PAGE
and in gel overlay assay. In stained SDS-gel, concentrated super-
natant of Sb-LecC gave a band of the same size as leucocin C
from L. lactis, between 4.6 and 10 kDa (Online Source 3a).
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According to the amino acid sequence, the calculated molecular
weight of leucocin C is 4.6 kDa. To confirm that the obtained
band was the active antimicrobial leucocin C, the supernatants
were loaded into another SDS-gel, which was subjected to over-
lay assay with L. monocytogenes. Sb-LecC supernatant and
leucocin C from L. lactis formed inhibition zones corresponding
to the bands in the stained SDS-gel (Online Source 3b). Neither
the supernatant of Sb-wild type nor the supernatant of Sb-vector
showed any inhibition. Therefore, it could be concluded that the
constructed Sb-LecC secretes leucocin C.
Growth of S. boulardii Strains
The effect of the introduced plasmids on growth was investi-
gated. Carrying heterologous plasmid made the lag phase lon-
ger and decreased the cell concentration in the stationary
growth phase of both Sb-LecC and Sb-vector strains, com-
pared with the wild-type strain (Fig. 2a). However, as there
was no significant difference between the growth of Sb-LecC
and Sb-vector strain, it can be deduced that the production of
the bacteriocin did not disturb the growth.
In order to determine whether the transformants could tol-
erate acidity similar to that in the human stomach, the growth
of S. boulardii strains was tested at pH 2 and pH 4. All three
S. boulardii strains grew in the same way at pH 4 as in YPD
medium without pH adjustment, but they could not grow at
pH 2 (Fig. 2b–d). Nevertheless, all the strains were still viable
after 24-h incubation at pH 2 (data not shown). These results
indicated that even though the growth of Sb-LecC and Sb-
vector was disturbed by introduced plasmids, their resistance
to low pH was maintained.
Killing of L. monocytogenes Without Selection
Pressure
The last aim in this study was to assess the killing capacity of
Sb-LecC, as well as to determine whether the strain can retain
its antimicrobial activity without selection pressure. To an-
swer these questions, S. boulardii strains were co-cultured
with serially diluted L. monocytogenes in media without
blasticidin S. As shown in Fig. 3a, S. boulardii Sb-LecC killed
Listeria effectively. When L. monocytogenes was incubated
with Sb-LecC at the initial Listeria concentration of 6.8 ×
107 CFU/ml, only 3% of Listeria cells were viable. With low-
er initial Listeria concentrations, no live cells were found.
Although Listeria count in liquid culture with Sb-LecC almost
doubled (1.83) at the initial cell concentration of 6.8 ×
108 CFU/ml, its survival ratio was much lower than when






































































Fig. 2 Growth of S. boulardii strains. a Growth curve of Sb-wild type,
Sb-vector, and Sb-LecC in YPDmedium. b–dGrowth curves of Sb-wild
type, Sb-vector, and Sb-LecC in YPD medium of pH 2 and pH 4. All
experiments were performed in triplicate. Data is presented as mean value
with standard deviation
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In addition, we wanted to examine if the killing efficiency
could be increased when the bacteriocin producing yeast and
Listeriawere closer to each other. To test that, S. boulardii and
Listeria cultures were mixed, the mixtures were centrifuged,
supernatants were removed, and the cell pellets were incubat-
ed per se to keep the cells in close contact. Compared with the
resul t s f rom liquid co-cul tures , Sb-LecC ki l led
L. monocytogenesmore effectively when the two strains were
incubated in pellet, also at the highest initial listerial cell con-
centration (Fig. 3b). The Sb-LecC strain killed 93% of Listeria
cells at the highest initial concentration of 6.8 × 108 CFU/ml.
At the initial concentration of 6.8 × 107 CFU/ml, the amount
of viable Listeria dropped after incubating with S. boulardii
Sb-LecC, with only a marginal survival ratio of 2 × 10−6. With
lower initial concentrations, no live L. monocytogenes cells
were found (Fig. 3b). Quite the opposite, when Listeria was
incubated without yeast cells, or with the S. boulardii vector
strain, Listeria counts increased after the incubation. These
results indicated that S. boulardii producing leucocin C killed
the pathogen L. monocytogenes without antibiotic selection
pressure and that the killing efficiency was higher when the
cells were in close proximity.
Discussion
In this study, the probiotic yeast S. boulardii CNCM I-745
was used as the host to secrete antilisterial peptide leucocin
C. Some of the unique features of S. boulardii make it a
superior drug delivery vehicle compared with other microor-
ganisms. For example, S. boulardii exhibits better heat and
acid tolerance than S. cerevisiae [1], making it a stronger
survivor under the harsh conditions in the gastrointestinal
tract. In addition, since S. boulardii is not a natural colonizer
in the intestine [1, 40], it can easily be removed after treatment
[41]. Moreover, nowadays yeast cultures can be produced in
large scale at low cost, which makes the genetically modified
S. boulardii an economical vehicle for drug delivery.
To realize the purposes mentioned above, it is essential to
examine or develop tools for genetic manipulation for
S. boulardii. To date, the genome sequences of a few
S. boulardii strains, such as ATCC MYA-796 [42], Unique
28, and CNCM I-745 [43], have been published, but the in-
formation about promoters or functional genes of S. boulardii
is still scarce. One of the few studies about S. boulardii genet-
ics is the work by Douradinha et al. [9], who confirmed the
existence of the constitutive promoters PGK1, PYK1, and
ENO1 in the genome of the strain ATCC MYA-796.
Therefore, genetic manipulation of S. boulardii mainly relies
on the genetic tools for S. cerevisiae. For example,
S. cerevisiae promoters like TEF1 and PGK1 [12], TDH3
[14], and Gal1 [15] were successfully applied for the heterol-
ogous protein expression in S. boulardii. In our study, expres-
sion of lecCwas mediated by the constitutive promoter TEF1,
which has been shown to be constantly active during cultiva-
tion [29, 30]. To facilitate the secretion of leucocin C, the
commonly used α-mating factor signal sequence [31] was
fused to the lecC gene. As for the selection marker, we have
previously tested the sensitivity of wild-type S. boulardii to
blasticidin S and determined its minimum lethal dose
(20 μg/ml) [28]. The successful secretion of leucocin C in
our study demonstrated that the TEF1 promoter and α-
mating factor signal sequence of S. cerevisiae can be used
for S. boulardii CNCM I-745. Yet, the vector used here is a
high copy number plasmid, which decreased the growth of the

























Fig. 3 Killing of Listeria by S. boulardii. a S. boulardii and
L. monocytogenes were co-cultured in the YPD medium with shaking.
b S. boulardii and L. monocytogenes were incubated in the form of cell
pellet after centrifugation to make a closer contact. The survival ratio of
L. monocytogenes after incubation is shown in charts. The cell density of
original L. monocytogenes culture was 6.8 × 109 CFU/ml, and then it was
diluted to 6.8 × 108–6.8 × 105 CFU/ml for incubation. The cell density of
S. boulardii added was 3.4 × 107 CFU/ml. All experiments were
performed in triplicate. All data is presented as mean value with
standard deviation
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LecC exhibited a prolonged lag phase and yielded a lower cell
density at the stationary phase (Fig. 2a) compared with the Sb-
wild type strain, even without the selective agent blasticidin S
in the medium (data not shown).
In SDS-PAGE and gel overlay assay, the leucocin C secreted
by Sb-LecC had a corresponding molecular weight and inhibi-
tion band between 4.6 and 10 kDa. These results are in consis-
tence with the results of Fu et al. [45] andWan et al. [27], which
both used L. lactis as the host. SDS-PAGE gives only a rough
estimation of the molecular weight [46], explaining inaccurate
results when molecular weight of leucocin C was determined
with SDS-PAGE. However, our aim here was only to demon-
strate the presence and activity of leucocin C in the Sb-LecC
supernatant, as when we tested its antimicrobial activity against
L. monocytogenes, it indeed gave an inhibition halo (Online
Source 2). These results revealed that S. boulardii is able to act
as a host to secrete heterologous and active leucocin C.
Undoubtedly, it is important that the yeast to be used as a probi-
otic survives and, if possible, is metabolically active in the gastroin-
testinal tract. In previous studies, S. boulardii has shown an en-
hanced growth compared with S. cerevisiae in media adjusted to
pH 4 [1, 47]. Thus, we investigated whether the transformants we
constructed could retain tolerance to low pH, resembling the condi-
tion in stomach. The Sb-LecC constructed in this study grewwell at
pH 4 (Fig. 2d), and it could recover after 24-h incubation at pH 2,
indicating that it survives the acidic conditions in human stomach
and can possibly regain its activity in human intestinal environment.
Thus, it seems possible that the leucocinC-secreting S. boulardiiwe
constructed can function as a vehicle to deliver leucocin C into the
small intestine. Correspondingly, S. boulardii may be modified to
secrete other recombinant therapeutics into human intestine.
Michael et al. [10] constructed an IL-10 producing S. boulardii
and tested its anti-inflammatory function in the colitis mice model.
No significant differences were observed between the treated and
untreatedmice groups, suggesting that IL-10was not secreted in the
intestine in sufficient quantities to decrease the inflammatory re-
sponse. A later research by Hudson et al. [13] demonstrated that
their GFP-producing recombinant S. boulardii strain could be re-
covered fromPeyer’s patches ofmice fedwith the strain and that the
isolated yeast cells had maintained their GFP production capacity.
Most recently, Bagherpour et al. [15] successfully applied anOVA-
producing S. boulardii to bring antigenic peptide ovalbumin into
intestinal lumen via mice oral administration and observed a signif-
icant increase of antibody response in treated group compared with
control groups. This work indicated the potential of this new deliv-
ery platform.
The use of probiotic microorganisms expressing antimicro-
bial peptides has been studied as a dual therapy to control
bacterial infectious diseases [48]. Probiotic bacteria like
Lactococcus lactis [49], Lactobacillus plantarum [50], and
Propionibacterium freudenreichii [51] have been successfully
applied as hosts to produce bacteriocin. As probiotic yeast,
S. boulardii has no direct antimicrobial effects, except binding
to some enteric pathogens like Salmonella [52], E. coli [53],
and Shigella [54]. In our case, we focused on improving the
probiotic effects of S. boulardii by adding the ability to kill
Listeria. Thus, the leucocin C expressed in this study enabled
S. boulardii to directly kill Listeria. As a foodborne pathogen,
L. monocytogenes can get into the human gastrointestinal
tract, interacting with intestinal epithelium [55, 56], and cause
gastroenteritis [57]. It is important to eliminate or prevent
L. monocytogenes in the human intestine. In this study, we
demonstrated that the Sb-LecC could efficiently kill
L. monocytogenes in vi t ro . When we incubated
L. monocytogenes and Sb-LecC cells in a pellet formed by
centrifugation, L. monocytogenes was killed more efficiently
compared with incubating free cells together in liquid culture.
Clearly, incubating the cells in the centrifugation pellet pro-
vides a better chance for cell contact and interactions, and
leucocin C could thereby easily reach the target. The concen-
tration of leucocin C in the cell pellet is likely to be higher than
when leucocin C is freely secreted to the growth medium,
which is the case when the two strains are co-cultured in a
liquid culture. The results also demonstrated that the leucocin
C secretion was relatively stable, as Sb-LecC was still secret-
ing active leucocin C even without selection pressure, and the
yield was enough to kill Listeria. Washing Sb-LecC cells
directly after they were separated from the growth medium
did not release leucocin C into the supernatant (data not
shown), suggesting that produced leucocin C does not stick
to the outer surface of Sb-LecC cells.
Taken together, our study showed that it is possible to add
antibacterial capacity to the probiotic yeast S. boulardii by
making it to secrete bacteriocin. In addition, we gave an in-
sight about the possibility of applying genetically engineered
S. boulardii as a carrier for therapeutics delivery. Further stud-
ies will focus on integrating the expression cassette into the
chromosome of the S. boulardii and future testing of their
improved probiotic effects in vivo in animal model.
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